OR WAIT null SECS
June 12, 2013
Conjugated vaccines are meeting the need for longer-lasting immune responses, but the production process is complex, and manufacturers are looking for simpler solutions.
May 30, 2013
GSK expands its vaccines platform technology expertise by acquiring Okairos, a Swiss-based company.
May 03, 2013
The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.
May 01, 2013
The authors describe a holistic and integrated approach to focus on the linkage of the prefilled syringe with the four phases of product design, development, operation, and control.
April 02, 2013
A Q&A with Tony Hitchcock, head of manufacturing at Cobra Biologics.
March 02, 2013
Vaccine development is benefiting from manufacturing advances and support for global health.
February 26, 2013
The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's six-in-one pediatric vaccine for marketing authorization.
February 19, 2013
Protein Sciences announced that the Biomedical Advanced Research and Development Authority (BARDA) will continue to support the company?s influenza vaccines program.
January 28, 2013
GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.
January 18, 2013
FDA has approved Protein Sciences's FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human flu vaccine. FDA approved Flublok for people 18–49 years old.